3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
Rituximab
25
Lenalidomide
21
Cyclophosphamide
20
Prednisone
14
obinutuzumab
12
Vincristine
12
Doxorubicin
11
Magnetic Resonance Spectroscopy
10
Bendamustine Hydrochloride
9
Specimen Handling
8
ibrutinib
7
Biopsy
7
fludarabine
6
pembrolizumab
5
fludarabine phosphate
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
zanubrutinib
4
venetoclax
4
tazemetostat
4
Whole-Body Irradiation
4
R-CHOP protocol
4
Prednisolone
3
Mycophenolic Acid
3
Etoposide
3
Cyclosporine
3
tisagenlecleucel
2
polatuzumab vedotin
2
orelabrutinib
2
loncastuximab tesirine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
UE2343
×
90 days
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled